Drug class
Parasympatholytics clinical trials
A class of medicines: the studies that test any of its 28 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the parasympatholytics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Anisodamine
- 2
- Hyoscyamine
- 2
- Telenzepine
- 1
- Octylonium
- 1
- Fenoverine
- 1
- Flavoxate
- 1
- Hydroquinidine
- 1
Studies by the year they started
541 studies that test it; most in 2017 (29)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 1 |
| 1998 | 2 |
| 1999 | 4 |
| 2000 | 4 |
| 2001 | 6 |
| 2002 | 23 |
| 2003 | 10 |
| 2004 | 8 |
| 2005 | 13 |
| 2006 | 25 |
| 2007 | 25 |
| 2008 | 20 |
| 2009 | 15 |
| 2010 | 22 |
| 2011 | 22 |
| 2012 | 21 |
| 2013 | 21 |
| 2014 | 19 |
| 2015 | 17 |
| 2016 | 27 |
| 2017 | 29 |
| 2018 | 21 |
| 2019 | 23 |
| 2020 | 18 |
| 2021 | 22 |
| 2022 | 29 |
| 2023 | 23 |
| 2024 | 19 |
| 2025 | 22 |
| 2026 | 29 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 208 · Other 334
Boehringer Ingelheim (89) · Assiut University (10) · Danish Headache Center (10) · GlaxoSmithKline (9) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company (7) · Jaeb Center for Health Research (7) · Mansoura University (7) · Cairo University (7)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 542
- A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia ControlRecruitingPhase 3Jaeb Center for Health ResearchNCT07095894Written as Atropine
- Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationRecruitingNot applicableChina National Center for Cardiovascular DiseasesNCT07877519Written as Atropine
- A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingPhase 4Bristol-Myers SquibbNCT07221877Written as Xanomeline/trospium chloride
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RecruitingPhase 3Bristol-Myers SquibbNCT07011732Written as Xanomeline/Trospium Chloride Capsule
- Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)RecruitingPhase 2Rehan AhmedNCT07816224Written as Atropine sulfate ophthalmic solution 0.005%
- A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsRecruitingPhase 1Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07204418Written as Xanomeline/ Trospium Chloride
- Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)RecruitingPhase 2Capital Medical UniversityNCT07800572Written as Anisodine Hydrobromide
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseRecruitingPhase 3Bristol-Myers SquibbNCT07011745Written as Xanomeline/Trospium Chloride Capsule
- Early Intervention for High Risk Premyopic ChildrenNot yet recruitingPhase 2National Yang Ming Chiao Tung University HospitalNCT07863713Written as 0.025% atropine eye drops
- Effect of Neural Constraints on Movement in StrokeRecruitingEarly Phase 1Northwestern UniversityNCT06666673Written as Tizanidine
- Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye DropsNot yet recruitingNot applicableRuihua WeiNCT07846787Written as 0.02% Atropine Sulfate Eye Drops
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingPhase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT07686263Written as Xanomeline/Trospium Chloride
- Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical TrialRecruitingPhase 3Ohio State UniversityNCT07567040Written as Atropine Sulfate 0.05% Oph Soln
- Postoperative Tizanidine Use in Pelvic Reconstructive Surgery: A Pilot StudyRecruitingPhase 2Hartford HospitalNCT07766837Written as Tizanidine
- PREterm Infants With Bronchial Obstruction - Prospective Study of Efficacy and Safety of Inhaled TiotropiumNot yet recruitingPhase 4General University Hospital, PragueNCT07827859Written as tiotropium bromide (Spiriva Respimat)
- Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for CholedocholithiasisRecruitingNot applicableRiga East Clinical University HospitalNCT07814976Written as Hyoscine Butylbromide
- The Effect of Preoperative Administration of Oral Tizanidine on the Postoperative Pain and Sleep QualityRecruitingNot applicableTanta UniversityNCT07800364Written as Tizanidine
- Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PKRecruitingEarly Phase 1Indiana UniversityNCT05789173Written as Methadone and Tizanidine
- A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending DosesRecruitingPhase 1Bristol-Myers SquibbNCT07063342Written as Xanomeline/Trospium Chloride Capsule
- Trimebutine Maleate for Enhancing Gastric Visualization in Acute Upper Gastrointestinal BleedingNot yet recruitingPhase 2/3Assiut UniversityNCT07749300Written as Trimebutine Maleate
See all 542 studies that test one of the parasympatholytics →
Codes
What other systems call Parasympatholytics · ClinicalTrials.gg INT007957
- MeSH (NLM) D010276ParasympatholyticsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D010276 | Parasympatholytics | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.